Cord blood is a valuable source of hematopoietic stem cells (HSCs) that can replace defective blood-forming and immune cells in people with inherited genetic and metabolic disorders. These stem cells have been used in transplantation medicine for decades. They offer a potentially life-saving treatment option for individuals affected by rare diseases that affect the blood, immune system, nervous system, or other organs.
HSCs can help restore normal cellular function by providing healthy donor cells, which have the potential to produce missing enzymes, correct immune deficiencies, and support the regeneration of healthy blood and immune systems.
Experts use cord blood stem cell transplantation in the treatment of several inherited genetic and metabolic disorders, such as sickle cell disease, thalassemia, Fanconi anemia, severe combined immunodeficiency (SCID), Hunter syndrome, Krabbe disease, metachromatic leukodystrophy (MLD), adrenoleukodystrophy, and various inherited bone marrow failure syndromes.
Current clinical studies show positive results, especially in children with metabolic disorders. These studies highlight that cord blood transplantation can help restore normal enzyme levels and slow or halt disease progression.
In various genetic and metabolic diseases, the body does not have sufficient healthy cells and is therefore unable to produce vital proteins, enzymes, or immune cells. When transplanted, cord blood stem cells have the potential to migrate to the bone marrow and start producing healthy blood and immune cells.
In metabolic disorders, donor-derived cells help offer functional enzymes that may lower the buildup of harmful substances in the body. This process can stabilize disease progression, improve organ function, and offer long-term health benefits.
